Ticagrelor: pharmacokinetic, pharmacodynamic and pharmacogenetic profile: an update
R Teng - Clinical pharmacokinetics, 2015 - Springer
Despite advancements in treatments for acute coronary syndromes over the last 10 years,
they continue to be life-threatening disorders. Currently, the standard of treatment includes …
they continue to be life-threatening disorders. Currently, the standard of treatment includes …
Clinical pharmacology of antiplatelet drugs
Introduction Platelets play a key role in arterial thrombosis and antiplatelet therapy is pivotal
in the treatment of cardiovascular disease. Current antiplatelet drugs target different …
in the treatment of cardiovascular disease. Current antiplatelet drugs target different …
Cytosorb adsorption during emergency cardiac operations in patients at high risk of bleeding
K Hassan, J Kannmacher, P Wohlmuth, U Budde… - The Annals of Thoracic …, 2019 - Elsevier
Background The purpose of this study was to analyze the results of Cytosorb (CytoSorbents,
Monmouth Junction, NJ) adsorption during emergency open heart operations in patients at …
Monmouth Junction, NJ) adsorption during emergency open heart operations in patients at …
Antibody-based ticagrelor reversal agent in healthy volunteers
Background Ticagrelor is an oral P2Y12 inhibitor that is used with aspirin to reduce the risk
of ischemic events among patients with acute coronary syndromes or previous myocardial …
of ischemic events among patients with acute coronary syndromes or previous myocardial …
Antiplatelet therapy for atherothrombotic disease in 2022—from population to patient-centered approaches
Antiplatelet agents, with aspirin and P2Y12 receptor antagonists as major key molecules,
are currently the cornerstone of pharmacological treatment of atherothrombotic events …
are currently the cornerstone of pharmacological treatment of atherothrombotic events …
Ticagrelor: clinical development and future potential
Platelets participate centrally in atherothrombosis, resulting in vessel occlusion and
ischaemia. Consequently, optimisation of antiplatelet regimens has the potential to further …
ischaemia. Consequently, optimisation of antiplatelet regimens has the potential to further …
Bentracimab for ticagrelor reversal in patients undergoing urgent surgery
Background Ticagrelor is a reversible oral P2Y12 platelet inhibitor used to treat patients with
acute coronary syndromes, prior myocardial infarction, high-risk coronary artery disease …
acute coronary syndromes, prior myocardial infarction, high-risk coronary artery disease …
Platelet-mimicking nanosponges for functional reversal of Antiplatelet agents
Background: During long-term antiplatelet agents (APAs) administration, patients with
thrombotic diseases take a fairly high risk of life-threatening bleeding, especially when in …
thrombotic diseases take a fairly high risk of life-threatening bleeding, especially when in …
Reversal and removal of oral antithrombotic drugs in patients with active or perceived imminent bleeding
Remarkable progress has been made in the pharmacological management of patients with
cardiovascular disease, including the frequent use of antithrombotic agents. Nonetheless …
cardiovascular disease, including the frequent use of antithrombotic agents. Nonetheless …
Comparison of two preventive dual antiplatelet regimens for unruptured intracranial aneurysm embolization with flow diverter/disrupter: a matched-cohort study …
Purpose Standard dual antiplatelet therapy (DAPT) for complex aneurysms treated with flow
diversion and flow disruption is acetylsalicylic acid (ASA) plus clopidogrel. However …
diversion and flow disruption is acetylsalicylic acid (ASA) plus clopidogrel. However …